美國NovaBios埃博拉診斷劑

廣州健侖生物科技有限公司

本公司專業供應各種進口品牌埃博拉病毒檢測試劑盒，包括美國的NovaBios、廣州創侖等CDC品牌。主要包括膠體金快檢、ELISA、PCR等方法學。歡迎咨詢

埃博拉病毒IgM、IgG、ELISA檢測試劑、埃博拉快速檢測試劑盒、

埃博拉病毒核酸檢測試劑盒（熒光探針PCR）

西非工作、旅游埃博拉檢測試劑盒

美國CDC使用的埃博拉診斷試劑——美國的NovaBios

美國NovaBios 埃博拉診斷試劑

【埃博拉簡介】

埃博拉（Ebola virus）又譯作伊波拉病毒。是一種十分罕見的病毒，1976年在蘇丹南部和剛果（金）（舊稱扎伊爾）的埃博拉河地區發現它的存在后，引起醫學界的廣泛關注和重視，“埃博拉”由此而得名。是一個用來稱呼一群屬于纖維病毒科埃博拉病毒屬下數種病毒的通用術語。是一種能引起人類和靈長類動物產生埃博拉出血熱的烈性傳染病病毒，有很高的死亡率，在50%至90%之間，致死原因主要為中風、心肌梗塞、低血容量休克或多發性器官衰竭。

埃博拉出血熱（EBHF）是由一種絲狀病毒感染導致的急性出血性、動物源性傳染病。1976年，埃博拉出血熱在非洲的蘇丹和扎伊爾暴發，病死率高達50% ～ 90% 。因該病始發于扎伊爾北部的埃博拉河流，并在該區域嚴重流行，故命名為埃博拉病毒，其形態學、致病性等與馬爾堡病毒相似，但免疫原性有所區別。

【產品介紹】

該產品是世界衛生組織（WHO）*個批準用于埃博拉病毒檢測的診斷試劑卡。不需要借助其他實驗儀器設備，只需要采取幾滴血清、血漿、血液樣品，既可以檢測，并在15分鐘內就可以得知結果是否感染埃博拉病毒。該產品具有靈敏度高、操作方便、實驗時間短等特點。

美國NovaBios 埃博拉診斷試劑

2014年8月，歐盟還將設置第二個“移動實驗室”，它有可能被運往塞拉利昂。
歐盟的這種“移動實驗室”一直就是為應對突發疫情而設計的。其檢測范圍覆蓋多種威脅巨大的病毒。埃博拉疫情使其有了發揮作用的實戰機會。從實戰中不斷總結埃博拉病毒特點，獲得數據，有助完善其診斷水平。而“移動”的特點，使該實驗室可以奔赴許多疫區，提高發現患者的效率。
診斷
埃博拉病毒潛伏期為2～21天，如何及早發現是關鍵。因此各國都在研發快速檢測法。中國在這方面表現突出。
中國已經具備了對埃博拉病毒進行及時檢測的診斷試劑研發能力。在抗體技術上，中國前期也已經有了很好的多元性抗體的制備能力，包括已經掌握了埃博拉病毒的抗體基因，啟動抗體的生產程序不會需要太長的時間。
中國在診斷試劑方面和抗體技術方面對埃博拉病毒是有備而來的。中國目前約有9個課題、10個埃博拉研究單位在從事埃博拉病毒研究，包括檢測方法、診斷試劑開發、疫苗和藥物等。這為我國應對埃博拉疫情提供了很好的，現在有很多試劑已經研發，很多方法和診斷試劑的技術儲備可隨時提供我國疾控部門應用。
治療
1.現狀
目前無有效疫苗，發現可疑患者應立即隔離，發現病猴應全部捕殺。死亡患者立即火化。埃博拉
治療手段只有對癥支持治療（靜脈輸液，血液和血小板輸注）。
其他方法包括輸注恢復健康埃博拉病毒感染者的血漿。這種方法的前提是康復患者的血漿中含有救命的中和抗體。根據此次疫情期間的報道，這種試驗性的治療手段已經在臨床運用，雖然該療法的療效未知。
2. 新藥進展
兩名感染埃博拉病毒的美國患者已*接受試驗性新藥治療，他們原本病情嚴重，但在使用名為ZMapp的藥物治療后病情開始好轉，其中*個接受治療的人甚至可以獨立行走，這讓醫學界看到了遏制埃博拉病毒的希望。盡管zui終療效還有待觀察，但至少說明人類有希望戰勝這種“大殺傷力”病毒。
在這兩名美國患者開始服用試驗性藥物之前，沒有任何埃博拉藥物或疫苗經過深入的臨床試驗，更不用說得到醫療管理機構認證并上市。
從公開的研究資料看，范圍內，相關藥物zui多也就是在侯子或部分健康人身上開展過初步測試。目前已知的只有兩種埃博拉藥物和一種疫苗在侯子身上測試后呈現不錯效果。研制這些產品的共有3家公司，其中兩家在美國，一家在加拿大，它們都曾接受美國衛生部門的資助。

美國NovaBios 埃博拉診斷試劑

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

想了解更多的NovaBios產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

In August 2014, the EU will also set up a second " lab", which could be shipped to Sierra Leone.
The EU's " lab" has been designed to respond to sudden outbreaks. Its detection range covers a wide range of global threats to the huge virus. The Ebola epidemic has a chance to play a real role. From the actual combat constantly sum up the characteristics of Ebola virus, access to the latest data, help improve the diagnostic level. The "" feature, so that the laboratory can go to many epidemic areas, improve the efficiency of the discovery of patients.
diagnosis
Ebola virus incubation period of 2 to 21 days, how early detection is the key. So countries around the world are developing rapid detection method. China is outstanding in this respect.
China has the ability to carry out timely testing of Ebola virus diagnostic reagents research and development capabilities. In antibody technology, China has also been a good early preparation of multiple antibodies, including the Ebola virus has been mastered the antibody gene, start the antibody production process will not take too long.
China is well prepared for the diagnosis of reagents and antibody technology for the Ebola virus. China currently has about nine issues, 10 Ebola research units engaged in Ebola virus research, including detection methods, diagnostic reagent development, vaccines and drugs. Which for our response to the Ebola epidemic provides a very good technical support, there are a lot of reagents have been developed, a lot of methods and diagnostic reagents technical reserves can be provided at any time China's disease control departments.
treatment
Status quo
There is no effective vaccine, found suspicious patients should be immediay isolated, found that the monkeys should be all killed. Death patients immediay cremated. Ebola
Treatment only symptomatic supportive therapy (intravenous infusion, blood and plaet transfusion).
Other methods include infusion of plasma to restore healthy Ebola virus infection. The premise of this method is that the patient's plasma contains a life-saving neutralizing antibody. According to the latest report during the epidemic, this experimental treatment has been in clinical use, although the efficacy of the therapy is unknown.
2. Advances in new drugs
Two American patients infected with Ebola virus have been the first to receive experimental new drug treatment, they were in serious condition, but in the use of drugs called ZMapp after treatment began to improve, the first person to receive treatment can even walk independently, This makes the medical community see the hope of curbing the Ebola virus. Although the final effect remains to be seen, but at least that human hope to overcome this "big lethal" virus.
No Ebola drug or vaccine undergo an in-depth clinical trial before the two US patients begin taking the trial drug, let alone certified and listed by the medical management agency.
From the open research data, the global scope, the relevant drugs up to that in the son or part of the healthy people who carried out a preliminary test. Currently known only two kinds of Ebola drugs and a vaccine in the son of the body after the test showed a good effect. There are three companies developing these products, two of which are in the United States and one in Canada, all of whom have received funding from the US health department.